Secukinumab for Psoriasis in a Patient With Familial Mediterranean Fever.

Patients with Familial Mediterranean fever (FMF) have a high prevalence of psoriasis. We report here the case of a 55-year-old Caucasian man with FMF and psoriasis. At presentation, the patient had a Psoriasis Area Severity Index (PASI) score of 14.6 with 25% body-surface area (BSA) involvement and a Dermatology Life Quality Index (DLQI) score of 10, indicating a moderate effect on quality of life. Treatment with secukinumab 300 mg was initiated with considerable improvement in the patient's skin condition observed after 4 weeks (PASI score 3.8, BSA involvement 4%, DLQI score 5), and a PASI score of 0 after approximately 12 months' treatment. To our knowledge, this is the first published report on the use of secukinumab in a patient with FMF and psoriasis, and demonstrates a potential role for secukinumab in the management of moderate-to-severe plaque psoriasis in patients with autoimmune/autoinflammatory conditions. This article is protected by copyright. All rights reserved.